Showing 3661-3670 of 7113 results for "".
- Vyne Therapeutics Doses First Patient in Phase 2b Vitiligo Trial of Novel BET Inhibitorhttps://practicaldermatology.com/news/vyne-therapeutics-doses-first-patient-phase-2b-vitiligo-trial-novel-bet-inhibitor/2467132/Vyne Therapeutics announced that the first subject has been dosed in a phase 2b trial evaluating VYN201 in subjects with either active or stable nonsegmental vitiligo. VYN201 is a novel pan-bromodomain and extra-terminal domain (BET) inhibitor designed for local administration. Topline data from
- Report: Advancements and Demand To Drive Aesthetic Medicine Market to $212.5 Billion by 2032https://practicaldermatology.com/news/advancements-and-demand-drive-aesthetic-medicine-market-2125-billion-2032/2463206/A new report forecasts growth in the aesthetic medicine market. Currently valued at US$ 75.6 billion, the report says that the value of the market is projected to reach US$ 212.5 billion by 2032, reflecting a robust compound annual growth rate of 12.17% from 2024 to 2032. The report attri
- Benign Nail Condition Linked to Cancer Riskhttps://practicaldermatology.com/news/benign-nail-condition-linked-cancer-risk/2463171/The presence of a benign nail abnormality may lead to the diagnosis of a rare inherited disorder that increases the risk of developing cancerous tumors of the skin, eyes, kidneys and the tissue that lines the chest and abdomen (eg, the mesothelium), according to scientists at the National Institu
- Humira Biosimilar Simlandi Now Available in the UShttps://practicaldermatology.com/news/humira-biosimilar-simlandi-now-available-us/2463126/Teva Pharmaceuticals and Alvotech announced the availability of Simlandi (adalimumab-ryvk) injection in the US as an interchangeable biosimilar to Humira. Simlandi is indicated for the treatment of adult plaque psoriasis and adult hidradenitis suppurativa, as well as adult rheumatoid arthritis, j
- Dermal Fillers Connected to Body Dysmorphia Disorder?https://practicaldermatology.com/news/dermal-fillers-connected-body-dysmorphia-disorder/2462981/A recent Forbes article suggests a potential connection between dermal fillers and body dysmorphic disorder (BDD), a condit
- Research Grant Supports Animal-Free Testing for Botoxhttps://practicaldermatology.com/news/research-grant-supports-animal-free-testing-botox/2462979/The National Center for Advancing Translational Services (NCATS) and the US Food and Drug Administration (FDA) awarded a $2 million research grant to develop an advanced testing platform capable of assessing the potency of botulinum toxin without the need for animal testing, according to a press
- Acne Vulgaris Market Projected to Eclipse $10 Billion by 2034https://practicaldermatology.com/news/acne-vulgaris-market-projected-eclipse-10-billion-2034/2462961/The acne vulgaris market reached a value of US$ 7.0 Billion in 2023 and is anticipated to grow at a CAGR of 3.23% to more than $10 billion by 2034, according to a report by the IMARC Group. The rising popularity of light-based and laser therapies is partially responsible for this growth,
- FDA Approves New Humira Biosimilar for Multiple Inflammatory Conditionshttps://practicaldermatology.com/news/fda-approves-new-adalimumab-adbm-formulation-multiple-inflammatory-conditions/2462933/Boehringer Ingelheim anounced that it has received FDA approval for a high-concentration, citrate-free formulation of Cyltezo® (adalimumab-adbm). According to a press release from the company, the approval enables an expansion of treatment options for chronic inflammatory diseases. This f
- Lilly Resubmits BLA for Lebrikizumabhttps://practicaldermatology.com/news/lilly-resubmits-bla-lebrikizumab/2462907/Eli Lilly and Company announced as part of its 2024 first-quarter financial report that it as resubmitted the biologic license application (BLA) for lebrikizumab to the U.S. Food and Drug Administration for the treatment of people 12 and older with moderate-to-severe atopic dermatitis (eczema), t
- EPI Health Issues Voluntary Recall of Several Products Following Bankruptcyhttps://practicaldermatology.com/news/epi-health-issues-voluntary-recall-several-products-following-bankruptcy/2462869/EPI Health (Novan) is initiating a voluntary recall of various within-expiry human drug products as a result of the closures and discontinuation of the post-marketing quality, regulatory and pharmacovigilance activities for these marketed products. The moves comes after EPI filed Chapter 7 bankru